Stay updated with breaking news from Uniqure. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UniQure (NASDAQ:QURE – Get Rating) – Equities research analysts at Cantor Fitzgerald reduced their FY2023 earnings per share (EPS) estimates for shares of uniQure in a report issued on Wednesday, May 10th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings of ($1.04) per share for the year, down from […] ....
1-800-FLOWERS.COM restated their maintains rating on shares of uniQure (NASDAQ:QURE – Get Rating) in a research note published on Tuesday, Benzinga reports. A number of other equities analysts have also recently commented on the stock. Chardan Capital cut their price target on shares of uniQure from $60.00 to $56.00 in a research note on Wednesday, […] ....
UniQure (NASDAQ:QURE – Get Rating)’s stock price traded down 6.6% on Tuesday . The stock traded as low as $20.18 and last traded at $20.24. 237,766 shares changed hands during trading, a decline of 57% from the average session volume of 546,811 shares. The stock had previously closed at $21.66. Wall Street Analyst Weigh In […] ....
Netherlands-based uniQure N.V said on Monday it would sell a portion of the royalty rights for its blood disorder gene therapy Hemgenix to HealthCare Royalty and Sagard Healthcare for up to $400. | May 15, 2023 ....
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an. | May 15, 2023 ....